LV12979B - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number: LV12979B
Authority: LV; Latvia
Prior art keywords: gbb; thp; butyrobetaine; gamma; pharmaceutical composition
Prior art date: 2001-09-07

Application number

LVP-01-134A

Other languages

English (en)

Latvian (lv)

Inventor

Ivars Kalvins

Maris Veveris

Anatolijs Birmans

Original Assignee

Ivars Kalvins

Maris Veveris

Anatolijs Birmans

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-09-07

Filing date

2001-09-07

Publication date

2003-05-20

2001-09-07 Application filed by Ivars Kalvins, Maris Veveris, Anatolijs Birmans filed Critical Ivars Kalvins

2001-09-07 Priority to LVP-01-134A priority Critical patent/LV12979B/en

2002-03-04 Priority to PL02368758A priority patent/PL368758A1/xx

2002-03-04 Priority to EP02702955A priority patent/EP1429753B1/de

2002-03-04 Priority to PCT/LV2002/000004 priority patent/WO2003022262A1/en

2002-03-04 Priority to PT02702955T priority patent/PT1429753E/pt

2002-03-04 Priority to AU2002236340A priority patent/AU2002236340B2/en

2002-03-04 Priority to ES02702955T priority patent/ES2280505T3/es

2002-03-04 Priority to AT02702955T priority patent/ATE350029T1/de

2002-03-04 Priority to EA200400386A priority patent/EA006675B1/ru

2002-03-04 Priority to CA2459719A priority patent/CA2459719C/en

2002-03-04 Priority to SI200230507T priority patent/SI1429753T1/sl

2002-03-04 Priority to DK02702955T priority patent/DK1429753T3/da

2002-03-04 Priority to DE60217369T priority patent/DE60217369T2/de

2002-03-04 Priority to KR1020047003366A priority patent/KR100841035B1/ko

2002-03-04 Priority to MXPA04002050A priority patent/MXPA04002050A/es

2002-03-04 Priority to JP2003526391A priority patent/JP4382480B2/ja

2002-03-04 Priority to US10/488,840 priority patent/US20040242590A1/en

2002-03-04 Priority to IL16073402A priority patent/IL160734A0/xx

2002-03-04 Priority to CNB028175077A priority patent/CN1275595C/zh

2002-03-04 Priority to HR20040328A priority patent/HRPK20040328B3/xx

2002-03-04 Priority to HK05100218.1A priority patent/HK1068003B/xx

2002-03-04 Priority to NZ532178A priority patent/NZ532178A/en

2002-08-29 Priority to MYPI20023224A priority patent/MY134074A/en

2002-09-04 Priority to ARP020103331A priority patent/AR036423A1/es

2002-09-05 Priority to TW091120239A priority patent/TWI224506B/zh

2002-09-05 Priority to JO200291A priority patent/JO2507B1/en

2003-05-20 Publication of LV12979B publication Critical patent/LV12979B/en

2004-03-04 Priority to IL160734A priority patent/IL160734A/en

2004-03-04 Priority to CU20040040A priority patent/CU23347B6/es

2004-04-05 Priority to MA27608A priority patent/MA27683A1/fr

2004-04-06 Priority to ZA200402702A priority patent/ZA200402702B/en

2004-04-07 Priority to BG108673A priority patent/BG108673A/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims abstract description 34
230000001568 sexual effect Effects 0.000 claims abstract description 21
229960003310 sildenafil Drugs 0.000 claims abstract description 17
241000124008 Mammalia Species 0.000 claims abstract description 13
230000000638 stimulation Effects 0.000 claims abstract description 11
JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 claims description 71
229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 8
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229960002381 vardenafil Drugs 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 2
238000010606 normalization Methods 0.000 claims 2
229940117229 cialis Drugs 0.000 claims 1
KQWXZVDGTJKULK-UHFFFAOYSA-N hydrazine;propanoic acid Chemical compound [NH3+]N.CCC([O-])=O KQWXZVDGTJKULK-UHFFFAOYSA-N 0.000 claims 1
WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 claims 1
241000700159 Rattus Species 0.000 abstract description 29
241001465754 Metazoa Species 0.000 abstract description 11
239000000203 mixture Substances 0.000 abstract description 8
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 abstract description 7
238000001990 intravenous administration Methods 0.000 abstract description 6
230000027326 copulation Effects 0.000 abstract description 5
230000037007 arousal Effects 0.000 abstract description 3
230000003247 decreasing effect Effects 0.000 abstract description 2
238000007920 subcutaneous administration Methods 0.000 abstract description 2
230000000699 topical effect Effects 0.000 abstract description 2
JHPNVNIEXXLNTR-UHFFFAOYSA-O 4-(trimethylammonio)butanoic acid Chemical compound C[N+](C)(C)CCCC(O)=O JHPNVNIEXXLNTR-UHFFFAOYSA-O 0.000 abstract 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 28
230000000694 effects Effects 0.000 description 21
229930008281 A03AD01 - Papaverine Natural products 0.000 description 14
229960001789 papaverine Drugs 0.000 description 14
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
239000000126 substance Substances 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 6
239000003651 drinking water Substances 0.000 description 5
235000020188 drinking water Nutrition 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000009258 post-therapy Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
230000006399 behavior Effects 0.000 description 3
PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 description 3
210000003899 penis Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
238000013019 agitation Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007894 caplet Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000003293 cardioprotective effect Effects 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
-1 pilis Substances 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960000835 tadalafil Drugs 0.000 description 2
IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
JQIYNMYZKRGDFK-RUFWAXPRSA-N Estradiol dipropionate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 JQIYNMYZKRGDFK-RUFWAXPRSA-N 0.000 description 1
229940122224 Gamma butyrobetaine hydroxylase inhibitor Drugs 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
208000006550 Mydriasis Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229960000711 alprostadil Drugs 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000009986 erectile function Effects 0.000 description 1
229950010215 estradiol dipropionate Drugs 0.000 description 1
230000012173 estrus Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
230000003370 grooming effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229960002937 meldonium Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
229960003207 papaverine hydrochloride Drugs 0.000 description 1
230000018052 penile erection Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
208000026451 salivation Diseases 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
208000008203 tachypnea Diseases 0.000 description 1
206010043089 tachypnoea Diseases 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LVP-01-134A 2001-09-07 2001-09-07 Pharmaceutical composition LV12979B (en)

Priority Applications (31)

Application Number	Priority Date	Filing Date	Title
LVP-01-134A LV12979B (en)	2001-09-07	2001-09-07	Pharmaceutical composition
US10/488,840 US20040242590A1 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
JP2003526391A JP4382480B2 (ja)	2001-09-07	2002-03-04	γ−ブチロベタインを含んで成る医薬組成物
PCT/LV2002/000004 WO2003022262A1 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
PT02702955T PT1429753E (pt)	2001-09-07	2002-03-04	Composição farmacêutica que compreende gama-butirobetaína
AU2002236340A AU2002236340B2 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
ES02702955T ES2280505T3 (es)	2001-09-07	2002-03-04	Composicion farmaceutica que comprende gamma-butirobetaina.
AT02702955T ATE350029T1 (de)	2001-09-07	2002-03-04	Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EA200400386A EA006675B1 (ru)	2001-09-07	2002-03-04	Фармацевтическая композиция, содержащая гамма-бутиробетаин
CA2459719A CA2459719C (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
SI200230507T SI1429753T1 (sl)	2001-09-07	2002-03-04	Farmacevtski sestavek, ki vsebuje gama-butirobetain
DK02702955T DK1429753T3 (da)	2001-09-07	2002-03-04	Farmaceutisk sammensætning omfattende gamma-butyrobetain
DE60217369T DE60217369T2 (de)	2001-09-07	2002-03-04	Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
KR1020047003366A KR100841035B1 (ko)	2001-09-07	2002-03-04	감마-부티로베타인을 포함하여 이루어지는 약제학적 조성물
MXPA04002050A MXPA04002050A (es)	2001-09-07	2002-03-04	Composicion farmaceutica comprendiendo gamma-butirobetaina.
PL02368758A PL368758A1 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
HR20040328A HRPK20040328B3 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
EP02702955A EP1429753B1 (de)	2001-09-07	2002-03-04	Pharmazeutische zusammensetzung enthaltend gamma-butyrobetain
CNB028175077A CN1275595C (zh)	2001-09-07	2002-03-04	含有γ－三甲铵基丁内盐的药物组合物
IL16073402A IL160734A0 (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
HK05100218.1A HK1068003B (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine
NZ532178A NZ532178A (en)	2001-09-07	2002-03-04	Pharmaceutical composition comprising gamma-butyrobetaine for treating erectile dysfunction
MYPI20023224A MY134074A (en)	2001-09-07	2002-08-29	Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence
ARP020103331A AR036423A1 (es)	2001-09-07	2002-09-04	Composicion farmaceutica.
TW091120239A TWI224506B (en)	2001-09-07	2002-09-05	Pharmaceutical composition
JO200291A JO2507B1 (en)	2001-09-07	2002-09-05	Pharmaceutical preparation
IL160734A IL160734A (en)	2001-09-07	2004-03-04	Pharmaceutical preparation containing gamma-butyrobtaine and its use
CU20040040A CU23347B6 (es)	2001-09-07	2004-03-04	Composición farmacéutica que comprende gamma-butirobetaína
MA27608A MA27683A1 (fr)	2001-09-07	2004-04-05	Composition pharmaceutique contenant de la gamma-butyrobetaine.
ZA200402702A ZA200402702B (en)	2001-09-07	2004-04-06	Pharmaceutical composition comprising gamma-butyrobetaine.
BG108673A BG108673A (en)	2001-09-07	2004-04-07	Pharmaceutical composition comprising gamma-butyrobetaine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
LVP-01-134A LV12979B (en)	2001-09-07	2001-09-07	Pharmaceutical composition

Publications (1)

Publication Number	Publication Date
LV12979B true LV12979B (en)	2003-05-20

Family

ID=19735292

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-01-134A LV12979B (en)	2001-09-07	2001-09-07	Pharmaceutical composition

Country Status (29)

Country	Link
US (1)	US20040242590A1 (de)
EP (1)	EP1429753B1 (de)
JP (1)	JP4382480B2 (de)
KR (1)	KR100841035B1 (de)
CN (1)	CN1275595C (de)
AR (1)	AR036423A1 (de)
AT (1)	ATE350029T1 (de)
AU (1)	AU2002236340B2 (de)
BG (1)	BG108673A (de)
CA (1)	CA2459719C (de)
CU (1)	CU23347B6 (de)
DE (1)	DE60217369T2 (de)
DK (1)	DK1429753T3 (de)
EA (1)	EA006675B1 (de)
ES (1)	ES2280505T3 (de)
HR (1)	HRPK20040328B3 (de)
IL (2)	IL160734A0 (de)
JO (1)	JO2507B1 (de)
LV (1)	LV12979B (de)
MA (1)	MA27683A1 (de)
MX (1)	MXPA04002050A (de)
MY (1)	MY134074A (de)
NZ (1)	NZ532178A (de)
PL (1)	PL368758A1 (de)
PT (1)	PT1429753E (de)
SI (1)	SI1429753T1 (de)
TW (1)	TWI224506B (de)
WO (1)	WO2003022262A1 (de)
ZA (1)	ZA200402702B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10325813B4 (de) *	2003-06-06	2007-12-20	Universitätsklinikum Freiburg	Prophylaxe und/oder Therapie bei der portalen Hypertonie
LV13450B (en) *	2004-08-24	2006-11-20	Grindeks As	Novel medicinal use of meldonium and pharmaceutical compositions thereof
AU2006275702A1 (en)	2005-07-29	2007-02-08	Concert Pharmaceuticals Inc.	Novel pharmaceutical compounds
WO2009095445A1 (en) *	2008-01-29	2009-08-06	Grindeks	New second medical use of 3-(2,2,2-trimethylhydrazine)propionate dihydrate
CN101781302B (zh) *	2009-05-31	2013-07-10	段波	一种磷酸二酯酶抑制剂和异黄酮形成的加成物及其应用
RU2622757C1 (ru) *	2016-06-02	2017-06-19	федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)	Способ лечения эректильной дисфункции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198434B (it) *	1981-01-06	1988-12-21	Sigma Tau Ind Farmaceuti	Composizione farmaceutica comprendente gamma butirrobetaina per il trattamento di sindromi da carenze di carnitina
LV11727B (en) *	1995-08-21	1997-08-20	Kalvins Ivars	Pharmaceutical composition
LV11728B (en) *	1995-08-21	1997-08-20	Kalvins Ivars	Pharmaceutical composition

2001
- 2001-09-07 LV LVP-01-134A patent/LV12979B/en unknown
2002
- 2002-03-04 NZ NZ532178A patent/NZ532178A/en unknown
- 2002-03-04 CN CNB028175077A patent/CN1275595C/zh not_active Expired - Fee Related
- 2002-03-04 DE DE60217369T patent/DE60217369T2/de not_active Expired - Lifetime
- 2002-03-04 ES ES02702955T patent/ES2280505T3/es not_active Expired - Lifetime
- 2002-03-04 HR HR20040328A patent/HRPK20040328B3/xx not_active IP Right Cessation
- 2002-03-04 MX MXPA04002050A patent/MXPA04002050A/es active IP Right Grant
- 2002-03-04 CA CA2459719A patent/CA2459719C/en not_active Expired - Fee Related
- 2002-03-04 PL PL02368758A patent/PL368758A1/xx unknown
- 2002-03-04 SI SI200230507T patent/SI1429753T1/sl unknown
- 2002-03-04 JP JP2003526391A patent/JP4382480B2/ja not_active Expired - Fee Related
- 2002-03-04 AU AU2002236340A patent/AU2002236340B2/en not_active Ceased
- 2002-03-04 PT PT02702955T patent/PT1429753E/pt unknown
- 2002-03-04 IL IL16073402A patent/IL160734A0/xx unknown
- 2002-03-04 EA EA200400386A patent/EA006675B1/ru not_active IP Right Cessation
- 2002-03-04 EP EP02702955A patent/EP1429753B1/de not_active Expired - Lifetime
- 2002-03-04 AT AT02702955T patent/ATE350029T1/de not_active IP Right Cessation
- 2002-03-04 DK DK02702955T patent/DK1429753T3/da active
- 2002-03-04 WO PCT/LV2002/000004 patent/WO2003022262A1/en not_active Ceased
- 2002-03-04 KR KR1020047003366A patent/KR100841035B1/ko not_active Expired - Fee Related
- 2002-03-04 US US10/488,840 patent/US20040242590A1/en not_active Abandoned
- 2002-08-29 MY MYPI20023224A patent/MY134074A/en unknown
- 2002-09-04 AR ARP020103331A patent/AR036423A1/es unknown
- 2002-09-05 TW TW091120239A patent/TWI224506B/zh not_active IP Right Cessation
- 2002-09-05 JO JO200291A patent/JO2507B1/en active
2004
- 2004-03-04 IL IL160734A patent/IL160734A/en not_active IP Right Cessation
- 2004-03-04 CU CU20040040A patent/CU23347B6/es unknown
- 2004-04-05 MA MA27608A patent/MA27683A1/fr unknown
- 2004-04-06 ZA ZA200402702A patent/ZA200402702B/en unknown
- 2004-04-07 BG BG108673A patent/BG108673A/xx unknown

Also Published As

Publication number	Publication date
US20040242590A1 (en)	2004-12-02
EA200400386A1 (ru)	2004-08-26
PL368758A1 (en)	2005-04-04
MXPA04002050A (es)	2004-06-07
DK1429753T3 (da)	2007-05-14
IL160734A (en)	2009-09-22
IL160734A0 (en)	2004-08-31
DE60217369T2 (de)	2007-08-23
BG108673A (en)	2005-03-31
ZA200402702B (en)	2005-05-11
MY134074A (en)	2007-11-30
ES2280505T3 (es)	2007-09-16
EA006675B1 (ru)	2006-02-24
CA2459719C (en)	2010-07-06
DE60217369D1 (de)	2007-02-15
NZ532178A (en)	2007-05-31
JP4382480B2 (ja)	2009-12-16
HRP20040328A2 (en)	2004-08-31
CA2459719A1 (en)	2003-03-20
SI1429753T1 (sl)	2007-06-30
HRPK20040328B3 (en)	2006-02-28
WO2003022262A1 (en)	2003-03-20
EP1429753B1 (de)	2007-01-03
CU23347B6 (es)	2009-02-20
JP2005504071A (ja)	2005-02-10
JO2507B1 (en)	2009-10-05
AR036423A1 (es)	2004-09-08
ATE350029T1 (de)	2007-01-15
KR20040034704A (ko)	2004-04-28
MA27683A1 (fr)	2006-01-02
KR100841035B1 (ko)	2008-06-24
PT1429753E (pt)	2007-04-30
AU2002236340B2 (en)	2008-06-12
CN1275595C (zh)	2006-09-20
EP1429753A1 (de)	2004-06-23
TWI224506B (en)	2004-12-01
CN1551764A (zh)	2004-12-01
HK1068003A1 (en)	2005-04-22

Publication	Publication Date	Title
JP2925326B2 (ja)	1999-07-28	ヒトの窒素保持の促進方法
WO1991007188A1 (en)	1991-05-30	Method for reducing blood cholesterol using arginine
JP2015007096A (ja)	2015-01-15	運動障害の予防および／または治療剤
KR20070111539A (ko)	2007-11-21	진성 당뇨병 치료용 로플루밀라스트
US20030187055A1 (en)	2003-10-02	Synergistic pharmaceutical combinations for treating obesity
CA2459719C (en)	2010-07-06	Pharmaceutical composition comprising gamma-butyrobetaine
US3557292A (en)	1971-01-19	Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
AU2002236340A1 (en)	2003-06-19	Pharmaceutical composition comprising gamma-butyrobetaine
LV12978B (en)	2003-05-20	Pharmaceutical composition
US3150044A (en)	1964-09-22	Treatment and composition for high blood pressure and palpitation
RU2165759C1 (ru)	2001-04-27	Средство для лечения алкогольной интоксикации
US20050009919A1 (en)	2005-01-13	Treating cachexia and excessive catabolism with (-)-hydroxycitric acid
HK1068003B (en)	2007-03-16	Pharmaceutical composition comprising gamma-butyrobetaine
EP4479027A1 (de)	2024-12-25	Pharmazeutische zusammensetzung und medikament mit l-tryptophan, l-5-hydroxytryptophan und einem inhibitor des peripheren abbaus
WO2017144978A1 (ru)	2017-08-31	Соли (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло [3.2.1]октана и оптически активных ацетиламинокислот, их применение для лечения ожирения
JP2527958B2 (ja)	1996-08-28	中枢神経障害治療剤
JPH06102624B2 (ja)	1994-12-14	非心臓由来の不整脈防止薬
JPS59184124A (ja)	1984-10-19	腎不全、糖尿病及び糖尿病性腎症におけるエネルギー代謝改善剤
JPWO1999030715A1 (ja)	2002-09-17	睡眠障害の予防・治療剤
WO2016075539A1 (ru)	2016-05-19	Композиция для лечения нарушений, связанных с избыточным весом или ожирением
EA026727B1 (ru)	2017-05-31	Соль (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана и фталевой кислоты, способ её получения, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением